Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on July 6, 2026

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Insignary Closes SBOM Accuracy Gap With Binary-Level Clarity for Regulatory Risk
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
Clinical Service Categories Defined for Individual and Family Care
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
ThreeSixty Journalism Kicks Off Multimedia Storytelling Institute Summer Program for Local High School Students
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
Stress management support tops Canadian workplace needs
L’accompagnement en matière de gestion du stress arrive en tête des besoins des employés canadiens
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Canada Diagnostic Centres, a Novacap Portfolio Company, Announces Acquisition of Shift Imaging
Catheter Precision, Inc. Announces Issuance of Two Key Patents
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
Rogers to Become 100% Owner of Maple Leaf Sports & Entertainment
Rogers en voie de devenir propriétaire unique de Maple Leaf Sports & Entertainment
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Alternative Medicine Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.